Kinugasa Yoshiharu, Ogino Kazuhide, Furuse Yoshiyuki, Shiomi Tetsuya, Tsutsui Hiroyuki, Yamamoto Tetsuya, Igawa Osamu, Hisatome Ichiro, Shigemasa Chiaki
Department of Cardiovascular Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Circ J. 2003 Sep;67(9):781-7. doi: 10.1253/circj.67.781.
It has been reported that the xanthine oxidase inhibitor, allopurinol, has a protective effect on ischemia - reperfusion injury, but the precise mechanism of its action is still unclear. Therefore, in the present study the mechanisms of the myocardial protection of allopurinol were evaluated in isolated perfused rat hearts. Allopurinol significantly inhibited myocardial xanthine oxidase activity, and improved left ventricular dysfunction after ischemia - reperfusion. In addition, the lactate dehydrogenase content in the coronary effluent obtained after reperfusion was significantly decreased. ATP, ADP, AMP and IMP significantly decreased, whereas inosine, hypoxanthine and xanthine significantly increased after ischemia in both the control and allopurinol groups. The concentration of xanthine was significantly decreased after ischemia - reperfusion in the allopurinol group; however, allopurinol did not affect the other purine metabolites. To evaluate the accumulation of oxidative stress, thiobarbituric acid reactive substances (TBARS) production in myocardial tissue was measured and allopurinol significantly decreased TBARS formation after ischemia - reperfusion. Finally, myocardial hydroxyl radicals were directly measured by electron spin resonance spectroscopy with the nitroxide radical 4-hydroxy-2, 2,6,6-tetramethyl-piperidine-N-oxyl. Hydroxyl radicals significantly increased immediately after reperfusion, but were significantly decreased in the allopurinol group. In conclusion, allopurinol reduced myocardial injury after ischemia-reperfusion by suppressing oxidative stress, but not by salvage of ATP. These findings may lead to the development of new therapeutic strategies for myocardial ischemia - reperfusion injury.
据报道,黄嘌呤氧化酶抑制剂别嘌呤醇对缺血-再灌注损伤具有保护作用,但其确切作用机制仍不清楚。因此,在本研究中,在离体灌注大鼠心脏中评估了别嘌呤醇心肌保护的机制。别嘌呤醇显著抑制心肌黄嘌呤氧化酶活性,并改善缺血-再灌注后的左心室功能障碍。此外,再灌注后获得的冠状动脉流出液中的乳酸脱氢酶含量显著降低。在对照组和别嘌呤醇组中,缺血后ATP、ADP、AMP和IMP显著降低,而肌苷、次黄嘌呤和黄嘌呤显著增加。别嘌呤醇组缺血-再灌注后黄嘌呤浓度显著降低;然而,别嘌呤醇不影响其他嘌呤代谢产物。为了评估氧化应激的积累,测量了心肌组织中硫代巴比妥酸反应性物质(TBARS)的产生,别嘌呤醇显著降低了缺血-再灌注后的TBARS形成。最后,用氮氧自由基4-羟基-2,2,6,6-四甲基哌啶-N-氧化物通过电子自旋共振光谱法直接测量心肌羟自由基。再灌注后羟自由基立即显著增加,但在别嘌呤醇组中显著降低。总之,别嘌呤醇通过抑制氧化应激而非挽救ATP来减轻缺血-再灌注后的心肌损伤。这些发现可能会导致开发针对心肌缺血-再灌注损伤的新治疗策略。